Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor

British Journal of Pharmacology

Volumn 162, Issue 4, 2011, Pages 947-960

  Cazorla, M ^a,b   Arrang, J M ^a   Premont J ^a,c  

^a CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^b College of Physicians and Surgeons ^*  (United States)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

agonist; antagonist; antibody; BDNF; brain disease; cancer; functional ligand; trkB receptor

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NEUROTROPHIN 3 RECEPTOR; NEUROTROPHIN RECEPTOR P75; POLYCLONAL ANTIBODY; PROTEIN KINASE B; PROTEIN TYROSINE KINASE A; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; LIGAND BINDING; MOUSE; NERVE CELL CULTURE; NERVE FIBER GROWTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; CHO CELLS; CRICETINAE; CRICETULUS; EMBRYO, MAMMALIAN; HUMANS; MICE; NEURITES; NEURONS; PC12 CELLS; RATS; RECEPTOR, TRKB; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 79251504626     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01094.x     Document Type: Article

References (40)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Banfield MJ, Naylor RL, Robertson AG, Allen SJ, Dawbarn D, Brady RL, (2001). Specificity in Trk receptor: neurotrophin interactions: the crystal structure of TrkB-d5 in complex with neurotrophin-4/5. Structure (Camb) 9: 1191-1199.
3. Benedetti M, Levi A, Chao MV, (1993). Differential expression of nerve growth factor receptors leads to altered binding affinity and neurotrophin responsiveness. Proc Natl Acad Sci USA 90: 7859-7863.
4. Cattaneo A, Capsoni S, Margotti E, Righi M, Kontsekova E, Pavlik P, et al. (1999). Functional blockade of tyrosine kinase A in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody. J Neurosci 19: 9687-9697.
5. Cazorla M, Jouvenceau A, Rose C, Guilloux JP, Pilon C, Dranovsky A, et al. (2010). Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice. PLoS One 5: e9777.
6. Chao MV, (2003). Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 4: 299-309.
7. Chao MV, Hempstead BL, (1995). p75 and Trk: a two-receptor system. Trends Neurosci 18: 321-326.
8. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, et al. (2006). Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 314: 140-143.
9. Clary DO, Weskamp G, Austin LR, Reichardt LF, (1994). TrkA cross-linking mimics neuronal responses to nerve growth factor. Mol Biol Cell 5: 549-563.
10. Desmet CJ, Peeper DS, (2006). The neurotrophic receptor TrkB: a drug target in anti-cancer therapy? Cell Mol Life Sci 63: 755-759.
11. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS, (2004). Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430: 1034-1039.
12. Durany N, Thome J, (2004). Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur Psychiatry 19: 326-337.
13. Geiger TR, Peeper DS, (2005). The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective. Cancer Res 65: 7033-7036.
14. Green SH, Rydel RE, Connolly JL, Greene LA, (1986). PC12 cell mutants that possess low- but not high-affinity nerve growth factor receptors neither respond to nor internalize nerve growth factor. J Cell Biol 102: 830-843.
15. Guillemard V, Ivanisevic L, Garcia AG, Scholten V, Lazo OM, Bronfman FC, et al. (2009). An agonistic mAb directed to the TrkC receptor juxtamembrane region defines a trophic hot spot and interactions with p75 coreceptors. Dev Neurobiol 70: 150-164.
16. Hempstead BL, Martin-Zanca D, Kaplan DR, Parada LF, Chao MV, (1991). High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. Nature 350: 678-683.
17. Huang EJ, Reichardt LF, (2001). Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24: 677-736.
18. Huang EJ, Reichardt LF, (2003). Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 72: 609-642.
19. Ilag LL, Lonnerberg P, Persson H, Ibanez CF, (1994). Role of variable beta-hairpin loop in determining biological specificities in neurotrophin family. J Biol Chem 269: 19941-19946.
20. Ip NY, Stitt TN, Tapley P, Klein R, Glass DJ, Fandl J, et al. (1993). Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells. Neuron 10: 137-149.
21. Klein R, Conway D, Parada LF, Barbacid M, (1990). The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. Cell 61: 647-656.
22. Kramer K, Gerald W, LeSauteur L, Saragovi HU, Cheung NK, (1997). Monoclonal antibody to human Trk-A: diagnostic and therapeutic potential in neuroblastoma. Eur J Cancer 33: 2090-2091.
23. Lafont F, Rouget M, Triller A, Prochiantz A, Rousselet A, (1992). In vitro control of neuronal polarity by glycosaminoglycans. Development 114: 17-29.
24. LeSauteur L, Maliartchouk S, Le Jeune H, Quirion R, Saragovi HU, (1996). Potent human p140-TrkA agonists derived from an anti-receptor monoclonal antibody. J Neurosci 16: 1308-1316.
25. Lu B, (2003). BDNF and activity-dependent synaptic modulation. Learn Mem 10: 86-98.
26. Lu B, Pang PT, Woo NH, (2005). The yin and yang of neurotrophin action. Nat Rev Neurosci 6: 603-614.
27. McNamara JO, Huang YZ, Leonard AS, (2006). Molecular signaling mechanisms underlying epileptogenesis. Sci STKE 2006: re12.
28. Mojsilovic-Petrovic J, Jeong GB, Crocker A, Arneja A, David S, Russell DS, et al. (2006). Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors. J Neurosci 26: 9250-9263.
29. Muragaki Y, Timothy N, Leight S, Hempstead BL, Chao MV, Trojanowski JQ, et al. (1995). Expression of trk receptors in the developing and adult human central and peripheral nervous system. J Comp Neurol 356: 387-397.
30. Murer MG, Yan Q, Raisman-Vozari R, (2001). Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 63: 71-124.
31. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM, (1994). Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 14: 759-767.
32. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM, (2002). Neurobiology of depression. Neuron 34: 13-25.
33. Pattarawarapan M, Burgess K, (2003). Molecular basis of neurotrophin-receptor interactions. J Med Chem 46: 5277-5291.
34. Perez P, Coll PM, Hempstead BL, Martin-Zanca D, Chao MV, (1995). NGF binding to the trk tyrosine kinase receptor requires the extracellular immunoglobulin-like domains. Mol Cell Neurosci 6: 97-105.
35. Pezet S, McMahon SB, (2006). Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 29: 507-538.
36. Poo MM, (2001). Neurotrophins as synaptic modulators. Nat Rev Neurosci 2: 24-32.
37. Qian MD, Zhang J, Tan XY, Wood A, Gill D, Cho S, (2006). Novel agonist monoclonal antibodies activate TrkB receptors and demonstrate potent neurotrophic activities. J Neurosci 26: 9394-9403.
38. Sadick MD, Galloway A, Shelton D, Hale V, Weck S, Anicetti V, et al. (1997). Analysis of neurotrophin/receptor interactions with a gD-flag-modified quantitative kinase receptor activation (gD.KIRA) enzyme-linked immunosorbent assay. Exp Cell Res 234: 354-361.
39. Shaltiel G, Chen G, Manji HK, (2007). Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol 7: 22-26.
40. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. (2001). Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293: 493-498.